Thoraflex Hybrid
FDA premarket approval P210006/S009 · decided 2024-08-01
Approval details
- PMA number
- P210006
- Supplement
- S009
- Supplement type
- Normal 180 Day Track No User Fee
- Supplement reason
- Postapproval Study Protocol
- Trade name
- Thoraflex Hybrid
- Generic name
- Hybrid stent graft, thoracic aortic lesion treatment
- Applicant
- Vascutek, Ltd.
- Date received
- 2024-07-03
- Decision date
- 2024-08-01
- Days to decision
- 29 days
- Decision code
- APPR
- Product code
- QSK
- Advisory committee
- Cardiovascular
- Expedited review
- No
- Location
- Inchinnan
- Statement
- approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P210006.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| Gelweave™ Vascular Prostheses (K241550) | Vascutek, Ltd. | 2025-02-27 |
| Gelsoft™ Plus Vascular Prostheses (K241070) | Vascutek, Ltd. | 2024-11-15 |
| Vascutek Gelsoft Plus ERS Vascular Graft (K202703) | Vascutek, Ltd. | 2021-04-06 |
| Vascutek Gelseal Patch, Vascutek Gelsoft Patch, Vascutek Thin Wall Carotid Patch (K200955) | Vascutek, Ltd. | 2020-07-08 |
| Gelseal Vascular Grafts, Gelsoft Vascular Grafts, Gelsoft Plus Vascular Grafts (K162803) | Vascutek, Ltd. | 2017-07-14 |
| Gelweave Vascular Grafts (K162794) | Vascutek, Ltd. | 2017-06-30 |
| GELWEAVE BRANCHED VASCULAR GRAFTS WITH RADIOPAQUE MARKERS (K093817) | Vascutek, Ltd. | 2010-01-07 |
| MAXIFLO, TAPERFLO (K092863) | Vascutek, Ltd. | 2009-10-08 |